Literature DB >> 19187826

Cerebrovascular accidents in ranibizumab.

Takashi Ueta1, Yasuo Yanagi, Yasuhiro Tamaki, Takuhiro Yamaguchi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19187826     DOI： 10.1016/j.ophtha.2008.09.046

Source DB:  PubMed          Journal:  Ophthalmology        ISSN： 0161-6420            Impact factor:   12.079


× No keyword cloud information.
  40 in total

Review 1.  Neurotoxicity of biologically targeted agents in pediatric cancer trials.

Authors:  Elizabeth M Wells; Amulya A Nageswara Rao; Joseph Scafidi; Roger J Packer
Journal:  Pediatr Neurol       Date:  2012-04       Impact factor: 3.372

2.  Long-term outcome of intravitreal pegaptanib sodium as maintenance therapy in Japanese patients with neovascular age-related macular degeneration.

Authors:  Maiko Inoue; Kazuaki Kadonosono; Akira Arakawa; Shin Yamane; Tatsuro Ishibashi
Journal:  Jpn J Ophthalmol       Date:  2015-03-04       Impact factor: 2.447

3.  Larger therapeutic window for steroid versus VEGF-A inhibitor in inflammatory angiogenesis: surprisingly similar impact on leukocyte infiltration.

Authors:  Shintaro Nakao; Souska Zandi; Nuria Lara-Castillo; Mahdi Taher; Tatsuro Ishibashi; Ali Hafezi-Moghadam
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-06-05       Impact factor: 4.799

4.  Bevacizumab vs ranibizumab-an appraisal of the evidence from CATT and IVAN.

Authors:  F G Ahfat; F H Zaidi
Journal:  Eye (Lond)       Date:  2013-03       Impact factor: 3.775

5.  SAVE-AMD: Safety of VEGF Inhibitors in Age-Related Macular Degeneration.

Authors:  Frank Enseleit; Stephan Michels; Isabella Sudano; Marc Stahel; Sandrine Zweifel; Oliver Schlager; Matthias Becker; Stephan Winnik; Matthias Nägele; Andreas J Flammer; Michel Neidhart; Nicole Graf; Christian M Matter; Burkhardt Seifert; Thomas F Lüscher; Frank Ruschitzka
Journal:  Ophthalmologica       Date:  2017-09-02       Impact factor: 3.250

6.  Photodynamic therapy combined with intravitreal bevacizumab and sub-tenon triamcinolone acetonide injections for age-related macular degeneration.

Authors:  Chikako Yoshizawa; Wataru Saito; Shigeki Hirose; Hirokuni Kitamei; Kousuke Noda; Susumu Ishida
Journal:  Jpn J Ophthalmol       Date:  2012-10-24       Impact factor: 2.447

7.  Association of Intravitreal Anti-Vascular Endothelial Growth Factor Therapy With Risk of Stroke, Myocardial Infarction, and Death in Patients With Exudative Age-Related Macular Degeneration.

Authors:  Lauren A Dalvin; Matthew R Starr; Jackson E AbouChehade; Gena M Damento; Maria Garcia; Saumya M Shah; David O Hodge; Irene Meissner; Sophie J Bakri; Raymond Iezzi
Journal:  JAMA Ophthalmol       Date:  2019-05-01       Impact factor: 7.389

Review 8.  Inflammatory mediators and angiogenic factors in choroidal neovascularization: pathogenetic interactions and therapeutic implications.

Authors:  Claudio Campa; Ciro Costagliola; Carlo Incorvaia; Carl Sheridan; Francesco Semeraro; Katia De Nadai; Adolfo Sebastiani; Francesco Parmeggiani
Journal:  Mediators Inflamm       Date:  2010-08-25       Impact factor: 4.711

9.  Therapeutic effect of oral bisphosphonates on choroidal neovascularization in the human eye.

Authors:  Shigeru Honda; Takayuki Nagai; Naoshi Kondo; Masahide Fukuda; Sentaro Kusuhara; Yasutomo Tsukahara; Akira Negi
Journal:  J Ophthalmol       Date:  2010-07-25       Impact factor: 1.909

10.  Pegaptanib sodium as maintenance therapy in neovascular age-related macular degeneration: the LEVEL study.

Authors:  Thomas R Friberg; Michael Tolentino; Pamela Weber; Sunil Patel; Scott Campbell; Mauro Goldbaum
Journal:  Br J Ophthalmol       Date:  2010-05-14       Impact factor: 4.638
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.